Allergologia et Immunopathologia · 2006 · 46 citations · 17 references
Life SciencesImmunologyPharmacologyAllergyHypersensitivityImmunotherapyAllergen ImmunotherapyAllergic RhinitisAllergic Rhinitis ManagementAllergic Rhinitis PharmacotherapyAllergy PharmacotherapyPollen AllergyAllergic Rhinitis ImmunotherapyImmunotherapy For Allergic DiseaseNasal Allergen ChallengePlacebo-controlled Efficacy AssessmentPollen AllergensPollen ImmunotherapyPollen-induced RhinitisSublingual Allergen Immunotherapy
BACKGROUND: The aim of this study was to confirm the clinical efficacy and safety of a preseasonal sublingual immunotherapy (SLIT) in a group of allergic patients with seasonal rhinoconjunctivitis with or without mild intermittent or mild persistent asthma. The immunotherapy was administered through the oral mucosa with a monomeric carbamylated allergoid (allergoid SLIT) for grass pollens. A secondary endpoint was to evaluate the effect of the allergoid SLIT on nasal reactivity. METHODS AND RESULTS: A single-center, randomized, double-blind, placebo-controlled study was performed. Patients were selected and randomly allocated to two groups: one group received active treatment (allergoid SLIT) for 2 years and the other received placebo. Both groups received the necessary drug treatment throughout the trial. Thirty-three outpatients (20 men and 13 women, mean age: 30 years; range: 19-43) attending our center were enrolled in the study. Symptoms and medications were scored on diary cards during the pollen season. An allergen nasal challenge was performed at baseline and after 2 years of SLIT to evaluate nasal reactivity. Because the clinical scores were non-normally distributed, the Mann-Whitney and the Chi-square tests for intergroup comparisons and the Wilcoxon test for intragroup comparisons were used. The results were evaluated after 1 and 2 years of treatment. Between the first and second years of treatment, no changes in the scores for the placebo group were found, while for the active vaccine group significant decreases were found in rhinorrhea (p < 0.03), sneezing (p < 0.03), and conjunctivitis (p < 0.02). Symptom scores after nasal challenge decreased (p < 0.03) after 2 years' treatment. Nasal steroid use significantly decreased in the active treatment group during May and June in both the years of treatment (p < 0.02). Only two mild local adverse events were reported in the active group and none was reported in the placebo group. CONCLUSIONS: The results of this study show that the allergoid SLIT is safe and effective in decreasing symptom scores and drug use in rhinitic patients allergic to grass pollen.
17
Veronica Varney, Qutayba Hamid, Mina Gaga et al. · Journal of Clinical Investigation · 1993 · 472 citations · Full text
Grass pollen immunotherapy: efficacy and safety during a 4‐year follow‐up study
Samantha Walker, Veronica Varney, Mina Gaga et al. · Allergy · 1995 · 152 citations
Othon Iliopoulos, David Proud, N. F. Adkinson et al. · Journal of Allergy and Clinical Immunology · 1991 · 144 citations · Full text
Marcello Bagnasco, Giuliano Mariani, Giovanni Passalacqua et al. · Journal of Allergy and Clinical Immunology · 1997 · 140 citations